Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.COTI to initiate Phase IB trial of SCLC drug
Preclinical results demonstrated that COTI-2 inhibited Akt/PKB phosphorylation in cancer cells resulting in apoptosis or programmed cell death and has shown excellent in vitro activity in several human
Preclinical results demonstrated that COTI-2 inhibited Akt/PKB phosphorylation in cancer cells resulting in apoptosis or programmed cell death and has shown excellent in vitro activity in several human
In this study of patients suffering from post-herpetic neuralgia, Eladur showed improved pain control versus placebo during the three-day continuous treatment period. In addition, Eladur appeared well tolerated
The POET-II (Essential Tremor II) program is a two-part registration program that will begin with a clinical study in subjects in up to 15 centers to acquire a
Published data on ranolazine’s mechanism suggests that during ischemic episodes excess sodium can flow into cardiac cells through sodium channels. This excess sodium can trigger a subsequent overload
Under terms of the agreement, which was announced on December 10, 2007, Volcano paid $25 million in cash at closing to CardioSpectra’s shareholders and warrant holders. In addition,
The deal with Biofisica will enable Sumed to enter the wound healing market and the announcement will see Sumed assume responsibility for sales, marketing and distribution of POSiFECT
Kalypsys will conduct a double-blind, placebo-controlled trial, which will enroll approximately 50 patients at 12-15 centers in the US, to demonstrate proof-of-concept for KD7040 as a treatment for
CovX’s biotherapeutic platform is a technology that links therapeutic peptides to an antibody ‘scaffold’. The peptide targets the disease while the antibody scaffold allows the peptide to remain
The National Association of Chain Drug Stores and the National Community Pharmacists Association sued the Centers for Medicare & Medicaid Services (CMS), asking the court to declare the
This orphan drug designation for Iplex grants Insmed seven years of market exclusivity upon approval for the myotonic muscular dystrophy (MMD) indication. In addition, Insmed is eligible for